


If this message is not displayed correctly, please visit the [webversion](#).



# TBMED

A testing bed for the development of high-risk medical devices.

## Newsletter Issue N° 5

Summer treated us well this year with the TBMED consortium coming back together for the first time in over 2.5 years. It was just wonderful! The meeting was followed by two major events: ESB 2022 and MedFit 2022 where our OITB go.Med was presented to the public for the first time! We hope you enjoy reading this 5th edition of the TBMED newsletter. And we have some special news right at the end!

### TBMED Consortium Meeting in Hannover, Germany



After 2.5 long years of online meetings, the TBMED consortium finally met in person again on June 28-29, 2022 in Hannover, Germany. With only slightly over a year to go, it was crucial at this point to get an overview of the current status of the OITB's development process and the progress with the project's use cases. It was a concise but vivid meeting which all partners present enjoyed very much.

■ [Find some impressions and more information here.](#)

### TBMED at ESB 2022



On September 4-8, 2022 ESB 2022 took place co-organized by Didier Letourneur from TBMED's partner INSERM. TBMED was present at the conference with a keynote speech on OITBs held by Iraida Loinaz (CIDETEC) during the "European Projects Symposia" and two posters: the first one prepared by Thomas Ritter (NUIG) on Human Corneal Keratocytes and the second one by Teresa Simon-Yarza on Quality-by-Design Driven Development of a Medical Device. All abstracts are available on the conference's website.

■ [Read a short recap of our activities at ESB2022!](#)

### OITB go.Med presented at MedFit




Our OITB **go.Med** had its first official appearance at MedFit exhibition in Grenoble, France, on September 20-21, 2022. TBMED representatives Iraida Loinaz and Andrea Haiek from the coordinating institution CIDETEC promoted go.Med at their exhibition booth and had the opportunity to discuss first hand with possible clients, providers and investors. It was a great occasion to show them all the potential that go.Med has to offer.

More information on go.Med and MedFit is available [here](#).

### Exciting new publication by our TBMED partner UNIZAR

#### *Iron Speciation in Animal Tissues Using AC Magnetic Susceptibility Measurements: Quantification of Magnetic Nanoparticles, Ferritin, and Other Iron-Containing Species*

The simultaneous detection and quantification of several iron-containing species in biological matrices is a challenging issue. In this work, AC magnetic susceptibility measurements are used to analyze different organs from an animal model that received a single intratumor administration of magnetic nanoparticles



The full publication is available [here](#).

### Heading for new shores



With the project reaching its final phase, we are now shifting our focus to our OITB **go.Med**. The TBMED newsletter in its present form will therefore be discontinued. You will receive its next edition in a brand-new go.Med layout! We are looking forward to sharing more news with you on our exciting way to found the Open Innovation Test Bed.

You will find more about go.Med on our [website](#).

### Events



**23rd EVER Congress** – October 13 – 15, 2022 in Valencia, Spain

**MEDICA 2022** – November 14 – 17, 2022 in Düsseldorf, Germany



**TBMED on Twitter**

*Impressum:*

*Eurice - European Research and Project Office GmbH*

*Heinrich-Hertz-Allee 1*

*66386 St. Ingbert*

*Unsubscribe from our newsletter*



TBMED has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 814439.